Ind-Swift Laboratories Ltd

Ind-Swift Laboratories Limited's investor presentation for the quarter ended September 30, 2026, highlights strong financial performance and strategic transformation. Management noted a 50% year-on-year increase in operating income, with operating EBITDA margin expanding to 18.02% and PAT margin to 13.21%. Sequentially, revenue and operating EBITDA grew by over 25%, with H1FY27 operating revenue reaching ₹420.97 crore, up 35.79%, and operating EBITDA growing more than 4x. The company transitioned from an API manufacturer to a focused FDF manufacturer, achieving a net-debt-free balance sheet and a ₹250 crore capex program funded internally. Strategic initiatives include deeper own-brand penetration in key export markets and the Samba EU-GMP upgrade. Management expects FY27 revenue growth of over 50%, a medium-term revenue CAGR of 20-25%, and EBITDA margin expansion of 200-300 BPS. The presentation details the company's evolution from an API-focused entity to a formulation-focused platform, with global regulatory approvals and a robust R&D pipeline targeting high-growth therapeutic areas. The balance sheet shows a net-debt-free position, with total assets of ₹1,754.29 crore as of H1FY27. The company also outlined its future growth plans, including expanding its product portfolio and increasing market presence in emerging regions.

The document emphasizes strong financial performance, strategic transformation, and positive growth expectations.